Abstract
M. M. Mocanu, R. M. Bell and D. M. Yellon. PI3 Kinase and not p42/p44 Appears to be Implicated in the Protection Conferred by Ischemic Preconditioning. Journal of Molecular and Cellular Cardiology (2002) 34, 661–668. Ischemic preconditioning results in an immediate phase of protection against lethal ischemia/reperfusion injury that is comprised of both irreversible necrosis and programmed cell death, apoptosis. We hypothesized that preconditioning may activate putative anti-apoptotic pathways, through the induction of either phosphatidyl inositol 3-OH kinase (PI3 kinase) or p42/p44 extracellular receptor kinase, attenuating total cell death. Isolated perfused rat hearts were preconditioned with two cycles of 5min ischemia and 10min reperfusion. Then they were frozen for Western blot analysis or subjected to 35min regional ischemia and 120min reperfusion prior to infarct size assessment. Selective PI3 kinase inhibitors, wortmannin (W, 100n M) and LY294002 (LY, 15μM) and the p42/p44 inhibitor, PD98059 (PD,10and 50μM), were individually infused during the preconditioning protocol. One further group of hearts received both inhibitors (W and PD). The results were expressed as percentage of infarction within the risk zone. Inhibition of PI3 kinase by either W or LYpartially abrogated the infarct sparing effect of ischemic preconditioning (I/R%: 44.6±2.7 in C, 17.6±2.0 in IP, vs 32.2±4.2 in W, and 30.9±2.6 in LY, P<0.05). Inhibition of ERK phosphorylation however, had no significant effect upon infarct size reduction (17.6±2.0 in ischemic preconditioning vs 21.4±3.0 in IP+10μM PD and 15.2±1.4 in IP+50μM PD, P>0.05). Western blot analysis confirmed that PD abrogated the phosphorylation of p42/p44 and LY the phosphorylation of AKT. Combined inhibition with PD+W failed to further attenuate protection (27.6±1.3%,P >0.1). These data appear to demonstrate that the PI3 kinase, but not the p42/p44 cascade, is implicated in early ischemic preconditioning.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
